{"id":"W3135168894","doi":"10.1200/jco.2021.39.6_suppl.tps372","title":"Phase III study evaluating efficacy and safety of MK-6482 + lenvatinib versus cabozantinib for second- or third-line therapy in patients with advanced renal cell carcinoma (RCC) who progressed after prior anti-PD-1/L1 therapy.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"ca_institutions":"Baker Hughes (Canada)","funders":"","keywords":"Cabozantinib; Lenvatinib; Medicine; Renal cell carcinoma; Oncology; Internal medicine; Targeted therapy; Tyrosine-kinase inhibitor; Systemic therapy; Clear cell renal cell carcinoma; Kidney cancer; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002469054,0.001904545,0.003099614,0.0005069062,0.0005247149,0.001419613,0.001353962,0.001814212,0.008320546],"category_scores_gemma":[0.001592265,0.0008753534,0.002337483,0.0005278413,0.001348355,0.001231009,0.0004872272,0.004561576,0.001764182],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.002002691,"about_ca_system_score_gemma":0.002891897,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001958976,"about_ca_topic_score_gemma":0.004539138,"domain_scores_codex":[0.9993804,0.0003128848,0.00002977153,0.0001039346,0.00005415228,0.0001188009],"domain_scores_gemma":[0.9984775,0.0002264669,0.0003687543,0.0001117873,0.0001200877,0.0006953366],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9384808,0.02746559,0.001867641,0.0005430183,0.001305794,0.00007338102,0.00008612918,0.001086525,0.00775176,0.0001408802,0.00233217,0.0188663],"study_design_scores_gemma":[0.8273249,0.1654963,0.003749306,0.00002693507,0.0004611178,0.00008604622,0.00003336643,0.0007894885,0.0007525342,0.0001721652,0.001091551,0.00001637468],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9802862,0.003322843,0.0009808728,0.0009976361,0.0004454751,0.007331137,0.00331241,0.0002267915,0.003096631],"genre_scores_gemma":[0.9799586,0.001812352,0.00213304,0.001476081,0.0003473558,0.006375121,0.003994278,0.00005890664,0.00384431],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.008320546,"threshold_uncertainty_score":0.02783495,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1325635417962137,"score_gpt":0.463206243036248,"score_spread":0.3306427012400343,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}